Zobrazeno 1 - 10
of 55
pro vyhledávání: '"35"'
Autor:
Lindsay D. Kumble, Garrett Lawlor, Aaron Oh, Simon Lichtiger, Timothy Wen, Maria T. Abreu, Adam S. Faye, Ravi P. Kiran, Chin Hur
Publikováno v:
Inflamm Bowel Dis
BackgroundIleal pouch–anal anastomosis (IPAA) is the mainstay of surgical treatment for patients with ulcerative colitis (UC) but is associated with an increased risk of infertility. We developed a simulation model examining the impact of initial s
Publikováno v:
Inflammatory Bowel Diseases. 21:2815-2824
BACKGROUND Restorative proctocolectomy with ileal pouch-anal anastomosis is the surgical treatment of choice for patients with medically refractory ulcerative colitis. Postsurgery, functional and inflammatory complications of the ileal pouch often oc
Publikováno v:
Inflammatory bowel diseases. 17(11)
Background: Children with inflammatory bowel disease (IBD) undergo imaging using ionizing radiation and may be exposed to high cumulative radiation. We hypothesized that children with IBD have high exposure to radiation from medical imaging. Methods:
Autor:
Martha Vander Vliet, Seymour Katz, Christopher Stevens, Dennis Riff, Robert Burakoff, William Y. Chey, Charles L. Krone, Eric W. Jacobson, Francis A. Farraye, Ronald E. Pruitt, Charles F. Barish, Ira Shafran, Matthew L. Sherman, Ronald Bleday
Publikováno v:
Inflammatory bowel diseases. 12(7)
Background: Intestinal inflammation associated with Crohn's disease is characterized by a type 1 helper T cell response and elevated levels of interleukin (IL)-12. We report our clinical experience with a novel oral IL-12/IL-23 inhibitor (STA 5326) f
Publikováno v:
Inflammatory bowel diseases. 10(3)
Background: Rarely, patchy right colonic inflammation has been observed in patients with left sided chronic ulcerative colitis (CUC), but the clinical significance of this finding is unknown. Therefore, the aim of this study was to evaluate the clini
Autor:
Laura E. Raffals, Gaurav Syal, Parakkal Deepak, Alexandra Gutierrez, Martin H. Gregory, Matthew A. Ciorba, George P. Christophi, Stephen B. Hicks, Kimberly N. Weaver, Edward L. Barnes, Poonam Beniwal-Patel, Patrick Hoversten, Devin Patel, Sowmya Palam, Hans H Herfarth
Publikováno v:
Inflamm Bowel Dis
Background and Aims Inflammation of the pouch after ileal pouch-anal anastomosis (IPAA) can significantly impact quality of life and be difficult to treat. We assessed the effectiveness and safety of vedolizumab in Crohn’s disease (CD) of the pouch
Autor:
Joel R. Rosh, Anne M. Griffiths, James Markowitz, Kajari Mondal, Suresh Venkateswaran, Madeline Bertha, Marla Dubinsky, Cary G. Sauer, Shervin Rabizadeh, Joshua D. Noe, Raguraj Chandradevan, Hari K. Somineni, Nusrat Harun, Subra Kugathasan, Scott B. Snapper, Cortney R. Ballengee, Wallace Crandall, Neal S. Leleiko, Lee A. Denson, Thomas D. Walters, Jeffrey S. Hyams, Tatyana Hofmekler, Mi-Ok Kim
Publikováno v:
Inflammatory Bowel Diseases. 24:2285-2290
Background Inflammatory bowel disease (IBD) mainly consists of Crohn's disease (CD) and ulcerative colitis (UC). About 10%-15% of patients with IBD cannot be firmly diagnosed with CD or UC; hence, they are initially diagnosed as inflammatory bowel di
Autor:
Patricio Escalante, Badr Al-Bawardy, Gregory R. Stroh, William A. Faubion, Konstantinos A. Papadakis, Guilherme Piovezani Ramos
Publikováno v:
Inflammatory Bowel Diseases. 24:2272-2277
Background Treatment for latent tuberculosis infection (LTBI) is of particular concern in patients with inflammatory bowel disease (IBD) initiating biologic therapies to prevent tuberculosis (TB) reactivation. This study aimed to evaluate the effecti
Autor:
Saartje, Van de Vondel, Filip, Baert, Christine, Reenaers, Stijn, Vanden Branden, Leila, Amininejad, Pieter, Dewint, Wouter, Van Moerkercke, Jean-François, Rahier, Pieter, Hindryckx, Peter, Bossuyt, Marc, Ferrante, S, Vermeire
Publikováno v:
Inflammatory bowel diseases, Vol. 24, no. 5, p. 1099-1105 (2018)
Background: Adalimumab (ADM) has been shown efficacious in ulcerative colitis (UC). In randomized controlled trials, dose escalation from 40 mg ADM every other week to 40 mg every week was required in 20%-25% of patients within 1 year. Real-life data
Autor:
Alexander Link, Ulrike von Arnim, Nha Le, Peter Malfertheiner, Christian Schulz, Katharina Schönauen
Publikováno v:
Inflammatory Bowel Diseases. 24:1547-1557
Background Assessment of the disease activity in inflammatory bowel disease (IBD) is essential for adequate treatment management and reliable noninvasive biomarkers for verification of mucosal healing are still needed. MicroRNAs (miRNAs) are differen